(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 March 2011 (17.03.2011)

PCT

(10) International Publication Number
WO 2011/031695 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 29/00* (2006.01)

(21) International Application Number:
PCT/US2010/048034

(22) International Filing Date:
8 September 2010 (08.09.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/240,783 9 September 2009 (09.09.2009) US
61/242,821 16 September 2009 (16.09.2009) US
61/317,839 26 March 2010 (26.03.2010) US

(71) Applicant *(for all designated States except US)*: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MACDONALD, Lynn** [US/US]; 16 Gedney Way, White Plains, NY 10605 (US). **MURPHY, Andrew, J.** [US/US]; 10 Newton Court, Croton-On-Hudson, NY 10502 (US). **PAPADOPULOS, Nicholas, J.** [US/US]; 59 Heritage Lane, Lagrangeville, NY 12540 (US). **MORRA, Marc, R.** [US/US]; 108 Foxton Court, Beacon Falls, CT 06403 (US). **SALZLER, Robert, R.** [US/US]; 567 Darby Glen Lane, Durham, CT 27713 (US). **LACCROIX-FRALISH, Michael, L.** [US/US]; 197 North Washingon Street, Apt. 3, Sleepy Hollow, NY 10591 (US).

(74) Agent: **COTTINGHAM, Frank**; Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN PROTEASE-ACTIVATED RECEPTOR-2




Fig. 5

(57) **Abstract**: The present invention provides antibodies that bind to protease-activated receptor-2 (PAR-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PAR-2. The antibodies of the invention are useful, *inter alia*, for the treatment of diseases and disorders associated with one or more PAR-2 biological activities, including the treatment of pain conditions, inflammatory conditions and gastrointestinal conditions.

WO 2011/031695 A1